<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365508</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000491296</org_study_id>
    <secondary_id>FCCC-FCRB-04-003-P</secondary_id>
    <secondary_id>05-818</secondary_id>
    <nct_id>NCT00365508</nct_id>
  </id_info>
  <brief_title>Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking</brief_title>
  <official_title>Comparing the Lozenge to the Patch for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may
      help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is
      more effective than counseling and the nicotine patch in helping adult smokers quit smoking.

      PURPOSE: This randomized phase III trial is studying counseling and the nicotine lozenge to
      see how well they work compared to counseling and the nicotine patch in helping smokers quit
      smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy of behavioral counseling and nicotine-replacement therapy with
           either oral nicotine lozenge (NL) or transdermal nicotine patch (NP), in terms of
           promoting rates of smoking cessation (e.g., continued abstinence), in adult smokers.

        -  Examine the degree to which nicotine replacement therapy (NRT) preference, desire to
           control NRT dosing, irregular smoking schedules, and desire for oral preoccupation
           moderates the relative efficacy of NL vs NP in promoting smoking cessation.

        -  Evaluate the impact of the NL on mediators of smoking cessation (i.e., reduced craving,
           diminished withdrawal symptoms, cue reactivity, and increased perceived control over
           withdrawal symptoms).

      Secondary

        -  Compare the rate of compliance with NRT across the 2 treatment arms and examine if
           compliance rate mediates the effects of NRT on quit rates.

        -  Examine the potential role of genes related to nicotine dependence such as genes related
           to nicotine metabolism enzymes (e.g., CYP1A1) or genes related to dopamine
           concentrations (e.g., DRD2).

      OUTLINE: This is a randomized, open-label, multicenter study. Participants are stratified
      according to study center. Participants are randomized to 1 of 2 intervention arms.

      All participants undergo smoking cessation counseling in weeks 1, 3, 5, 7, and 9. Beginning
      in week 3, participants are asked to quit smoking for 12 weeks (weeks 3-14).

        -  Arm I: Participants apply a transdermal nicotine patch at 3 different time periods
           during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is
           applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.

        -  Arm II: Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9
           lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and
           1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).

      The moderating variables (e.g., nicotine replacement-therapy [NRT] preference and the
      smoker's desire to control NRT dosing) are assessed at baseline. The mediating variables
      (i.e., reduced craving, diminished withdrawal symptoms, cue reactivity, and increased
      perceived control over withdrawal symptoms) are assessed at baseline and then at weeks 5, 7,
      9, within weeks 14-16, and within weeks 26-28. Continuous abstinence will be measured at week
      27.

      PROJECTED ACCRUAL: A total of 700 participants will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Point Prevalence Abstinence at the 6-month Follow up</measure>
    <time_frame>6-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Compliance During the First 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Applied to use of the intervention (number of lozenges/day or number of patches used per week) not considering abstinence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine lozenge</intervention_name>
    <description>nicotine lozenge</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine patch</intervention_name>
    <description>transdermal nicotine patch</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>transdermal nicotine patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Smokes at least 10 cigarettes a day on average for the past year

          -  No prior diagnosis of cancer (unless completed treatment AND no evidence of disease
             within the past 5 years)

          -  Able to use nicotine replacement therapy

        PATIENT CHARACTERISTICS:

          -  Able to communicate in English

          -  Must reside in the geographic area for ≥ 6 months

          -  Current asthma, ulcer, or diabetes allowed provided medical clearance from the
             participant's physician is obtained

          -  No evidence of drug or alcohol abuse

          -  No known HIV positivity

          -  No heart disease, including any of the following:

               -  Current diagnosis of coronary artery disease

               -  Abnormal heart rhythm or an arrhythmia

               -  Heart failure

               -  Heart valve disease

               -  Congenital heart disease

               -  Heart muscle disease or cardiomyopathy

               -  Pericardial disease

               -  Aorta disease

               -  Vascular disease

               -  Myocardial infarction

               -  High blood pressure (defined as blood pressure &gt; 140/90 mm Hg) not receiving
                  antihypertensive medication

                    -  History of or current high blood pressure controlled by antihypertensive
                       medication and having medical clearance from physician allowed

          -  No allergy to adhesive tape or latex

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile participants must use effective contraception during and for ≥ 1 month prior
             to and after completion of study treatment

        PRIOR CONCURRENT THERAPY:

          -  At least 30 days since prior and no concurrent benzodiazepine (e.g., diazepam,
             alprazolam, or lorazepam)

          -  At least 6 months since prior antiretroviral medications

          -  At least 6 months since prior and no concurrent medication for depression (e.g.,
             phenelzine sulfate, pargyline hydrochloride, tranylcypromine sulfate, paroxetine
             hydrochloride, sertraline hydrochloride, fluoxetine hydrochloride)

          -  No concurrent antipsychotics (e.g., lithium) or theophylline

          -  No concurrent substance abuse treatment

          -  No concurrent bupropion hydrochloride

          -  No other concurrent pharmacologic aid or any other form of formal assistance for
             smoking cessation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Schnoll, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center - Cheltenham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060-2099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York, PC - Northeast Center</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057-4510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Don Monti Comprehensive Cancer Center at North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Main Line Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville General Hospital at Meharry</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <results_first_submitted>November 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>adult primary liver cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>tongue cancer</keyword>
  <keyword>tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through ads/physician referral at: FCCC, Geisinger Medical Center, Hematology Oncology Associates of Central NY, Howard University, LSU, Main Line Health System, Medical College of GA, Meharry Medical College, Mount Sinai Medical Center (Miami), North Shore University, SUNY Downstate Medical Center, and Virtua Health.</recruitment_details>
      <pre_assignment_details>1299 individuals were screened for this trial over 4 years; 454 individuals were ineligible, 194 refused enrollment, and 651 were randomized. Nine individuals either withdrew from the study prior to treatment or were found to be ineligible after randomization and were removed from the intent-to-treat sample. The final ITT sample was 642 (321/arm).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Patch</title>
          <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Lozenge</title>
          <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="321"/>
            <count group_id="B2" value="321"/>
            <count group_id="B3" value="642"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="12.7"/>
                    <measurement group_id="B2" value="44.8" spread="11.9"/>
                    <measurement group_id="B3" value="44.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-hour Point Prevalence Abstinence at the 6-month Follow up</title>
        <time_frame>6-months</time_frame>
        <population>Intent to treat analysis (lost to follow-up = smoker)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
          </group>
        </group_list>
        <measure>
          <title>24-hour Point Prevalence Abstinence at the 6-month Follow up</title>
          <population>Intent to treat analysis (lost to follow-up = smoker)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square was used to examine the relationship between treatment arm and 24-hour point prevalence abstinence at 6-months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>a priori threshold for statistical significance</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Compliance During the First 2 Weeks</title>
        <description>Applied to use of the intervention (number of lozenges/day or number of patches used per week) not considering abstinence</description>
        <time_frame>2 weeks</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Compliance During the First 2 Weeks</title>
          <description>Applied to use of the intervention (number of lozenges/day or number of patches used per week) not considering abstinence</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Administered a checklist of side effects from NRT and collected any additional information on adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>heart attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>killed in car accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abcessed tooth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was an effectiveness trial so external vs. internal validity was emphasized. Many participants were lost to follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Schnoll</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7143</phone>
      <email>schnoll@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

